Edition:
United States

Stemline Therapeutics Inc (STML.O)

STML.O on Consolidated Issue listed on NASDAQ Capital Market

6.85USD
24 Feb 2017
Change (% chg)

$0.40 (+6.20%)
Prev Close
$6.45
Open
$6.45
Day's High
$6.90
Day's Low
$6.40
Volume
171,675
Avg. Vol
287,973
52-wk High
$14.60
52-wk Low
$3.88

STML.O

Chart for STML.O

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.11
Market Cap(Mil.): $162.01
Shares Outstanding(Mil.): 23.65
Dividend: --
Yield (%): --

Financials

  STML.O Industry Sector
P/E (TTM): -- 44.08 29.63
EPS (TTM): -2.17 -- --
ROI: -46.89 -3.35 12.96
ROE: -47.17 5.80 14.11

BRIEF-Stemline Therapeutics provides update on pivotal BPDCN trial

* Stemline therapeutics provides update on pivotal bpdcn trial

Feb 02 2017

BRIEF-Stemline Therapeutics reports Q3 financial results

* Stemline Therapeutics reports third quarter 2016 financial results and highlights recent regulatory and clinical progress

Nov 08 2016

BRIEF-Stemline announces seven presentations

* Stemline announces seven presentations, including oral presentation of updated SL-401 phase 2 BPDCN data, at upcoming ASH meeting Source text for Eikon: Further company coverage:

Nov 03 2016

More From Around the Web

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,531 +1.50
Eisai Co., Ltd (4523.T) ¥6,306 +65.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,997 +4.00
Pfizer Inc. (PFE.N) $34.26 +0.20
Novartis AG (NOVN.S) CHF77.60 0.00
Merck & Co., Inc. (MRK.N) $66.16 +0.31
Roche Holding Ltd. (ROG.S) CHF245.20 +0.10
Roche Holding Ltd. (RO.S) CHF248.50 +0.30
Sanofi SA (SASY.PA) €80.58 +0.45
GlaxoSmithKline plc (GSK.L) 1,639.50 +7.00

Earnings vs. Estimates